We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Register to vote Register by 18 June to vote in the General Election on 4 July.
Gwybodaeth a rheolau amdanoch chi a'ch beic.
DASA has launched a new competition to trial the cutting-edge CHERI security architecture in a defence and security context
Employment Tribunal decision.
Fund will help to develop proposals to build or reopen railway lines and stations.
Recombinant human erythropoietin (r-HuEPO) treatment has been associated with very rare cases of life-threatening severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Withdraw r-HuEPOs permanently in patients who develop severe skin reactions such as...
Upper Tribunal Administrative Appeals Chamber decision by Judge Jacobs on 10 November 2021.
Takeda UK Ltd is recalling specific batches of Rienso 30mg/ml solution for infusion (Ferumoxytol).
Patients with cancer who received recombinant human erythropoietins in clinical trials had an increased risk of tumour progression and reduced overall survival compared with study controls.
Over-correction of haemoglobin concentration may increase the risk of death and serious cardiovascular events in patients with chronic kidney disease; it may increase the risk of thrombosis and related complications in patients with cancer.
Patients with pulmonary hypertension associated with idiopathic interstitial pneumonias should not be treated with riociguat in light of interim results from a recently terminated study.
Upper Tribunal Tax and Chancery decision of Judge Bishopp, Member O’Neill and Member Chapman on 28 September 2012.
We worked with RBS to help Chemian Technology access working capital to meet growing international demand for its products.
The CMA has found that Iconex’s purchase of two rival receipt paper suppliers Schades and R+S may lead to less choice and higher prices.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).